JPWO2020264425A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020264425A5 JPWO2020264425A5 JP2021577919A JP2021577919A JPWO2020264425A5 JP WO2020264425 A5 JPWO2020264425 A5 JP WO2020264425A5 JP 2021577919 A JP2021577919 A JP 2021577919A JP 2021577919 A JP2021577919 A JP 2021577919A JP WO2020264425 A5 JPWO2020264425 A5 JP WO2020264425A5
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic
- haptics
- ophthalmic article
- item
- iol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Description
[0641]本発明の好ましい実施形態が、本明細書において示され、記載される一方、このような実施形態が例示のみの目的で提供されることは、当業者に明らかであろう。本発明が、明細書内で提供される具体的な実施例により限定されることは、意図されていない。本発明は、上述の明細書を参照して記載される一方、本明細書における実施形態の記載および説明は、限定的な意味で作成されるつもりはない。多数のバリエーション、変更、および置換は、本発明から逸脱することなく、当業者に思い浮かび得る。さらに、本発明のすべての態様は、様々な条件および変数に依存する、本明細書において記載される具体的な描写、配置または相対的比率に限定されないことは、理解されるだろう。本明細書において記載される本発明の実施形態の様々な代替が、本発明の実施において利用され得ることは、理解されるべきである。故に、本発明はまた、任意のかかる代替、改変、バリエーションまたは均等物をカバーすることが企図される。以下の特許請求の範囲が、本発明の範囲を定義すること、およびこれらの請求の範囲内の方法および構造物ならびにそれらの均等物が、これによりカバーされることが、意図される。本明細書は以下の発明の開示を包含する。
［項目１］ａ．カプロラクトンモノマーおよび少なくとも１種の他のモノマーに由来するコポリマーを含む生体適合性マトリックスと、
ｂ．活性剤または診断剤と
を含む眼科用物品であって、眼内レンズ（ＩＯＬ）のハプティクスに結合するように構成されている眼科用物品。
［項目２］前記コポリマーが、約２０重量％～約６０重量％の前記カプロラクトンモノマーおよび約４０重量％～８０重量％の前記少なくとも１種の他のモノマーに由来する、項目１に記載の眼科用物品。
［項目３］前記コポリマーが、約４０重量％の前記カプロラクトンモノマーおよび約６０重量％の前記少なくとも１種の他のモノマーに由来する、項目１または２に記載の眼科用物品。
［項目４］前記少なくとも１種の他のモノマーが、ラクチド、グリコリド、またはトリメチレンカーボネートである、前記項目のいずれか一項に記載の眼科用物品。
［項目５］前記コポリマーが、ランダムコポリマーを含む、前記項目のいずれか一項に記載の眼科用物品。
［項目６］前記活性剤が、デキサメタゾン、ケトロラック、ジクロフェナク、モキシフロキサシン、トラボプロスト、５－フルオロウラシル、またはメトトレキセートである、前記項目のいずれか一項に記載の眼科用物品。
［項目７］ａ．生体適合性材料と、
ｂ．活性剤または診断剤と
を含む眼科用物品であって、約４０重量％のカプロラクトンモノマーおよび約６０重量％のラクチドモノマーに由来するコポリマーを含む生体適合性マトリックスを含む別の物品と等価な弾性、圧縮性、引張強さ、形状回復性、または再成形性を有し、眼内レンズ（ＩＯＬ）のハプティクスに結合するように構成されている眼科用物品。
［項目８］前記生体適合性マトリックスを含む前記別の物品が、少なくとも約０．５メガパスカル（ＭＰａ）の引張強さを有する、項目７に記載の眼科用物品。
［項目９］前記生体適合性マトリックスを含む前記別の物品が、示差走査熱量測定法によって測定して最大でも約２４℃のガラス転移温度を有する、項目７または８に記載の眼科用物品。
［項目１０］前記生体適合性マトリックスを含む前記別の物品が、示差走査熱量測定法によって測定して約－２０℃～２４℃のガラス転移温度を有する、前記項目のいずれか一項に記載の眼科用物品。
［項目１１］前記生体適合性マトリックスを含む前記別の物品が、最大でも約３ＭＰａの弾性率を有する、前記項目のいずれか一項に記載の眼科用物品。
［項目１２］前記生体適合性マトリックスを含む前記別の物品が、約０．５ＭＰａ～３ＭＰａの弾性率を有する、前記項目のいずれか一項に記載の眼科用物品。
［項目１３］前記生体適合性マトリックスを含む前記別の物品が、約１８℃～２４℃で測定して少なくとも約１００％の破断点伸びを有する、前記項目のいずれか一項に記載の眼科用物品。
［項目１４］前記生体適合性マトリックスを含む前記別の物品が、約１８℃～２４℃で約５００％～１５００％の破断点伸びを有する、前記項目のいずれか一項に記載の眼科用物品。
［項目１５］前記ＩＯＬの前記ハプティクスの周囲に結合するための内部構造を含む、前記項目のいずれか一項に記載の眼科用物品。
［項目１６］前記内部構造の周囲長または最大幅が、前記ＩＯＬの前記ハプティクスの周囲長または最大幅以下である、項目１５に記載の眼科用物品。
［項目１７］ａ．（１）カプロラクトンモノマーおよび少なくとも１種の他のモノマーに由来するコポリマーを含む生体適合性マトリックス、ならびに（２）１種または複数の活性剤または診断剤を含む１つまたは複数の眼科用物品と、
ｂ．１つまたは複数のハプティクスを含む１つまたは複数の眼内レンズ（ＩＯＬ）と
を含む眼科用送達システムであって、前記１つまたは複数の眼科用物品が、前記ＩＯＬの前記１つまたは複数のハプティクスに結合している、眼科用送達システム。
［項目１８］前記１つまたは複数の眼科用物品の約１つが、前記ＩＯＬの前記１つまたは複数のハプティクスと結合している、項目１７に記載の眼科用送達システム。
［項目１９］前記１つまたは複数の眼科用物品の約１つが、前記ＩＯＬの前記１つまたは複数のハプティクスの１つと結合している、項目１７または１８に記載の眼科用送達システム。
［項目２０］前記コポリマーが、約２０重量％～約６０重量％の前記カプロラクトンモノマーおよび約４０重量％～８０重量％の前記少なくとも１種の他のモノマーに由来する、前記項目のいずれか一項に記載の眼科用送達システム。
［項目２１］前記コポリマーが、約４０重量％の前記カプロラクトンモノマーおよび約６０重量％の前記少なくとも１種の他のモノマーに由来する、前記項目のいずれか一項に記載の眼科用送達システム。
［項目２２］前記少なくとも１種の他のモノマーが、ラクチド、グリコリド、またはトリメチレンカーボネートである、前記項目のいずれか一項に記載の眼科用送達システム。
［項目２３］前記１種または複数の活性剤が、デキサメタゾン、ケトロラック、ジクロフェナク、モキシフロキサシン、トラボプロスト、５－フルオロウラシル、またはメトトレキセートである、前記項目のいずれか一項に記載の眼科用送達システム。
［項目２４］前記１つまたは複数の眼科用物品が、前記ＩＯＬの前記１つまたは複数のハプティクスの周囲に結合するための内部構造を含む、前記項目のいずれか一項に記載の眼科用送達システム。
［項目２５］前記内部構造の周囲長または最大幅が、前記ＩＯＬの前記１つまたは複数のハプティクスの周囲長または最大幅以下である、項目２４に記載の眼科用送達システム。
［項目２６］疾患を処置または予防する方法であって、それを必要とする対象の眼に持続性眼内薬物送達のための眼内レンズ（ＩＯＬ）を埋め込むステップを含み、ＩＯＬが、それに結合している１つまたは複数の薬物放出物品を含み、前記１つまたは複数の薬物放出物品が、１種または複数の活性剤を含み、埋め込み後７日以内に、前記１つまたは複数の薬物放出物品が、前記１種または複数の活性剤を放出し、その結果、細隙灯生体顕微鏡法を使用して前房細胞スコアによって測定して炎症スコアが最大でも１になり、または１０点視覚的アナログ尺度によって測定して眼痛がなくなる、方法。
［項目２７］埋め込み後７日以内に、前記１つまたは複数の薬物放出物品が、前記１種または複数の活性剤を放出し、その結果、細隙灯生体顕微鏡法を使用して前房細胞スコアによって測定して炎症スコアが最大でも１になる、項目２６に記載の方法。
［項目２８］埋め込み後７日以内に、前記１つまたは複数の薬物放出物品が、前記１種または複数の活性剤を放出し、その結果、１０点視覚的アナログ尺度によって測定して眼痛がなくなる、項目２６または２７に記載の方法。
［項目２９］前記１つまたは複数の薬物放出物品が、前記ＩＯＬの１つまたは複数のハプティクスに結合している、前記項目のいずれか一項に記載の方法。
［項目３０］前記１つまたは複数の薬物放出物品の１つが、前記ＩＯＬの前記１つまたは複数のハプティクスの１つと結合している、項目２９に記載の方法。
［項目３１］前記１つまたは複数の薬物放出物品の２つが、前記ＩＯＬの前記１つまたは複数のハプティクスの１つと結合している、項目２９に記載の方法。
［項目３２］前記１つまたは複数の薬物放出物品が、生体適合性マトリックスを含む、前記項目のいずれか一項に記載の方法。
［項目３３］前記生体適合性マトリックスが、約２０重量％～約６０重量％のカプロラクトンモノマーおよび約４０重量％～８０重量％の少なくとも１種の他のモノマーに由来するコポリマーを含む、項目３２に記載の方法。
［項目３４］前記１つまたは複数の薬物放出物品が、約１μｇ～８００μｇの前記１種または複数の活性剤を含む、前記項目のいずれか一項に記載の方法。
［項目３５］前記１種または複数の活性剤が、デキサメタゾン、ケトロラック、ジクロフェナク、モキシフロキサシン、トラボプロスト、５－フルオロウラシル、またはメトトレキセートである、前記項目のいずれか一項に記載の方法。
［項目３６］前記対象が、眼科手術を同時に受けているまたは受けたことがある、前記項目のいずれか一項に記載の方法。
［項目３７］前記対象が、白内障手術を同時に受けているまたは受けたことがある、前記項目のいずれか一項に記載の方法。
［項目３８］少なくとも１つの作用剤放出眼内レンズを調製する方法であって、
（ａ）１種または複数の活性剤または診断剤を、カプロラクトンモノマーおよび少なくとも１種の他のモノマーに由来するコポリマーを含む生体適合性マトリックスと組み合わせ、それによって１つまたは複数の眼科用物品を生成するステップと、
（ｂ）前記１つまたは複数の眼科用物品を少なくとも１つの眼内レンズ（ＩＯＬ）の１つまたは複数のハプティクスに結合させるステップと
を含む方法。
［項目３９］前記１つまたは複数の眼科用物品の約１つが、前記ＩＯＬの前記１つまたは複数のハプティクスの１つと結合している、項目３８に記載の方法。
［項目４０］前記１つまたは複数の眼科用物品の約２つが、前記ＩＯＬの前記１つまたは複数のハプティクスの１つと結合している、項目３８または３９に記載の方法。
［項目４１］前記生体適合性マトリックスが、約２０重量％～約６０重量％のカプロラクトンモノマーおよび約４０重量％～８０重量％の少なくとも１種の他のモノマーに由来するコポリマーを含む、前記項目のいずれか一項に記載の方法。
［項目４２］前記１つまたは複数の眼科用物品が、引張試験によって測定して少なくとも約１００％の破断点伸びを有する、前記項目のいずれか一項に記載の方法。
［項目４３］前記１種または複数の活性剤が、デキサメタゾン、ケトロラック、ジクロフェナク、モキシフロキサシン、トラボプロスト、５－フルオロウラシル、またはメトトレキセートである、前記項目のいずれか一項に記載の方法。
［項目４４］前記結合が、前記１つまたは複数の眼科用物品と前記１つまたは複数のハプティクスとの間の間接的結合を含む、前記項目のいずれか一項に記載の方法。
［項目４５］前記１つまたは複数の眼科用物品が、前記１つまたは複数のハプティクスの周囲に結合するための内部構造を含む、前記項目のいずれか一項に記載の方法。
［項目４６］前記内部構造の周囲長または最大幅が、前記１つまたは複数のハプティクスの周囲長または最大幅以下である、項目４５に記載の方法。
［項目４７］活性剤または診断剤を投与する方法であって、
（ａ）１つまたは複数の眼科用物品が結合している眼内レンズ（ＩＯＬ）を約０．５ｍｍ～３ｍｍのインジェクターチップ内径を含むＩＯＬインジェクターを通して圧縮し、それによって１つまたは複数の眼科用物品が結合している圧縮されたＩＯＬを生成するステップであって、１つまたは複数の眼科用物品が、１種または複数の活性剤または診断剤を含む、ステップと、
（ｂ）活性剤または診断剤の投与を必要とする対象の眼に、１つまたは複数の眼科用物品が結合している前記圧縮されたＩＯＬを持続性眼内活性剤または診断剤送達のために埋め込むステップと
を含む方法。
［項目４８］前記１つまたは複数の眼科用物品が、生体適合性マトリックスを含む、項目４７に記載の方法。
［項目４９］前記生体適合性マトリックスが、約２０重量％～約６０重量％のカプロラクトンモノマーおよび約４０重量％～８０重量％の少なくとも１種の他のモノマーに由来するコポリマーを含む、項目４８に記載の方法。
［項目５０］前記生体適合性マトリックスが、約０．５ｍｍ～３ｍｍのインジェクターチップ内径を含むＩＯＬインジェクターによる注入と適合するように十分に圧縮可能である、項目４８または４９に記載の方法。
［項目５１］前記１つまたは複数の眼科用物品が、少なくとも約０．５メガパスカル（ＭＰａ）の引張強さを有する、項目４８から５０のいずれか一項に記載の方法。
［項目５２］前記１つまたは複数の眼科用物品が、示差走査熱量測定法によって測定して最大でも約２４℃のガラス転移温度を有する、前記項目のいずれか一項に記載の方法。
［項目５３］前記１つまたは複数の眼科用物品が、最大でも約３ＭＰａの弾性率を有する、前記項目のいずれか一項に記載の方法。
［項目５４］前記１つまたは複数の眼科用物品が、引張試験によって測定して少なくとも約１００％の破断点伸びを有する、前記項目のいずれか一項に記載の方法。
［項目５５］前記圧縮が、前記１つまたは複数の眼科用物品が結合している前記ＩＯＬを、約０．５ｍｍ～３ｍｍの前記インジェクターチップ内径を含む前記ＩＯＬインジェクターを通して管状に折り畳むステップを含む、前記項目のいずれか一項に記載の方法。
［項目５６］（１）カプロラクトンモノマーおよび少なくとも１種の他のモノマーに由来するコポリマーを含む生体適合性マトリックス、ならびに（２）１種または複数の活性剤または診断剤を含む１つまたは複数の眼科用物品を含む容器と、
使用説明書と
を含むキット。
［項目５７］１つまたは複数の眼内レンズを含む別の容器をさらに含み、前記１つまたは複数の眼内レンズのそれぞれが、１つまたは複数のハプティクスを含む、項目５６に記載のキット。
［項目５８］前記容器が、前記１つまたは複数の眼科用物品と結合している１つまたは複数のハプティクスを含む１つまたは複数の眼内レンズをさらに含む、項目５６に記載のキット。
［項目５９］前記１つまたは複数の眼科用物品の１つが、前記１つまたは複数のハプティクスと結合している、項目５７または５８に記載のキット。
［項目６０］前記１つまたは複数の眼科用物品の２つが、前記１つまたは複数のハプティクスと結合している、項目５７または５８に記載のキット。
［項目６１］前記コポリマーが、約２０重量％～約６０重量％の前記カプロラクトンモノマーおよび約４０重量％～８０重量％の前記少なくとも１種の他のモノマーに由来する、前記項目のいずれか一項に記載のキット。
［項目６２］前記１種または複数の活性剤が、デキサメタゾン、ケトロラック、ジクロフェナク、モキシフロキサシン、トラボプロスト、５－フルオロウラシル、またはメトトレキセートである、前記項目のいずれか一項に記載のキット。
［項目６３］１つまたは複数の眼内デバイスインジェクターをさらに含む、前記項目のいずれか一項に記載のキット。
［項目６４］眼の疾患または状態を診断する方法であって、それを必要とする対象の眼に、１種または複数の診断剤を対象の眼に送達するための眼内レンズ（ＩＯＬ）を投与するステップを含み、ＩＯＬが、それに結合している１つまたは複数の眼科用物品を含み、前記１つまたは複数の眼科用物品が、常磁性分子、蛍光化合物、磁性分子、放射性核種、ｘ線イメージング剤、および造影剤からなる群から選択される前記１種または複数の診断剤を含む、方法。
［項目６５］前記疾患または状態を示す前記１種または複数の診断剤を含むイメージを捕獲するステップをさらに含む、項目６４に記載の方法。
［項目６６］１つまたは複数の眼科用物品が結合している前記ＩＯＬを投与するより前に、前記１つまたは複数の眼科用物品を前記ＩＯＬの１つまたは複数のハプティクスに結合させるステップを含む、項目６４または６５に記載の方法。
［項目６７］前記１つまたは複数の眼科用物品が結合している前記ＩＯＬを投与するより前に、１種または複数の診断剤を生体適合性マトリックスと組み合わせ、それによって前記１つまたは複数の眼科用物品を生成するステップを含む、前記項目のいずれか一項に記載の方法。
［項目６８］前記１つまたは複数の眼科用物品が結合している前記ＩＯＬを投与するより前に、前記１つまたは複数の眼科用物品が結合している前記ＩＯＬを、約０．５～３ｍｍのインジェクターチップ内径を含むＩＯＬインジェクターを通して圧縮するステップを含む、前記項目のいずれか一項に記載の方法。
［項目６９］前記１種または複数の診断剤が、蛍光化合物である、前記項目のいずれか一項に記載の方法。
［項目７０］前記１つまたは複数の眼科用物品が、生体適合性コポリマーマトリックスを含む、前記項目のいずれか一項に記載の方法。
［項目７１］前記生体適合性マトリックスが、約２０重量％～約６０重量％のカプロラクトンモノマーおよび約４０重量％～８０重量％の少なくとも１種の他のモノマーに由来するコポリマーを含む、項目７０に記載の方法。
[0641] While preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided for purposes of illustration only. It is not intended that the invention be limited by the specific examples provided within the specification. While the present invention has been described with reference to the foregoing specification, the descriptions and illustrations of the embodiments herein are not meant to be taken in a limiting sense. Numerous variations, modifications, and substitutions may occur to those skilled in the art without departing from the invention. Furthermore, it will be understood that all aspects of the present invention are not limited to the specific depictions, arrangements or relative proportions set forth herein which are dependent on various conditions and variables. It should be understood that various alternatives to the embodiments of the invention described herein may be utilized in practicing the invention. Accordingly, the invention is also intended to cover any such alternatives, modifications, variations or equivalents. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby. This specification includes the disclosure of the following inventions.
[Item 1] a. a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer;
b. An ophthalmic article comprising an active agent or diagnostic agent, the ophthalmic article configured to bind to haptics of an intraocular lens (IOL).
[Item 2] The ophthalmic product of item 1, wherein the copolymer is derived from about 20% to about 60% by weight of the caprolactone monomer and about 40% to 80% by weight of the at least one other monomer. Goods.
3. The ophthalmic article of claim 1 or 2, wherein said copolymer is derived from about 40% by weight of said caprolactone monomer and about 60% by weight of said at least one other monomer.
[Item 4] The ophthalmic article according to any one of the above items, wherein the at least one other monomer is lactide, glycolide, or trimethylene carbonate.
[Item 5] The ophthalmic article of any one of the preceding items, wherein the copolymer comprises a random copolymer.
[Item 6] The ophthalmic article of any one of the preceding items, wherein the active agent is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate.
[Item 7] a. a biocompatible material;
b. an ophthalmic article comprising an active agent or diagnostic agent, the elasticity equivalent to another article comprising a biocompatible matrix comprising a copolymer derived from about 40% by weight caprolactone monomers and about 60% by weight lactide monomers; An ophthalmic article that is compressible, tensile strength, shape recoverable, or remoldable and configured to bond to the haptics of an intraocular lens (IOL).
8. The ophthalmic article of claim 7, wherein said another article comprising said biocompatible matrix has a tensile strength of at least about 0.5 megapascals (MPa).
9. The ophthalmic article of claim 7 or 8, wherein said another article comprising said biocompatible matrix has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry.
[Item 10] Any one of the preceding items, wherein the another article comprising the biocompatible matrix has a glass transition temperature of about -20°C to 24°C as measured by differential scanning calorimetry. ophthalmic articles.
[Item 11] The ophthalmic article of any one of the preceding items, wherein the another article comprising the biocompatible matrix has a modulus of elasticity of at most about 3 MPa.
[Item 12] The ophthalmic article of any one of the preceding items, wherein the another article comprising the biocompatible matrix has an elastic modulus of about 0.5 MPa to 3 MPa.
[Item 13] The ophthalmic use of any one of the preceding items, wherein the another article comprising the biocompatible matrix has an elongation at break of at least about 100% measured at about 18°C to 24°C. Goods.
[Item 14] The ophthalmic article of any one of the preceding items, wherein the another article comprising the biocompatible matrix has an elongation at break of about 500% to 1500% at about 18°C to 24°C. .
[Item 15] The ophthalmic article of any one of the preceding items, including an internal structure for coupling around the haptics of the IOL.
[Item 16] The ophthalmic article of item 15, wherein the perimeter or maximum width of the internal structure is equal to or less than the perimeter or maximum width of the haptics of the IOL.
[Item 17] a. (1) a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer; and (2) one or more ophthalmic articles comprising one or more active or diagnostic agents;
b. and one or more intraocular lenses (IOLs) containing one or more haptics, wherein the one or more ophthalmic articles are the one or more lenses of the IOLs. An ophthalmic delivery system coupled to haptics.
[Item 18] The ophthalmic delivery system of Item 17, wherein about one of the one or more ophthalmic articles is associated with the one or more haptics of the IOL.
[Item 19] The ophthalmic delivery system of item 17 or 18, wherein about one of the one or more ophthalmic articles couples with one of the one or more haptics of the IOL.
[Item 20] Any one of the preceding items, wherein the copolymer is derived from about 20% to about 60% by weight of the caprolactone monomer and about 40% to 80% by weight of the at least one other monomer. The ophthalmic delivery system according to .
[Item 21] The ophthalmic delivery system of any one of the preceding items, wherein the copolymer is derived from about 40% by weight of the caprolactone monomer and about 60% by weight of the at least one other monomer.
[Item 22] The ophthalmic delivery system of any one of the preceding items, wherein the at least one other monomer is lactide, glycolide, or trimethylene carbonate.
[Item 23] The ocular delivery of any one of the preceding items, wherein the one or more active agents is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. system.
[Item 24] The ophthalmic delivery of any one of the preceding items, wherein the one or more ophthalmic articles comprise an internal structure for coupling around the one or more haptics of the IOL. system.
25. The ophthalmic delivery system of claim 24, wherein the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of the one or more haptics of the IOL.
[Item 26] A method of treating or preventing a disease comprising implanting an intraocular lens (IOL) for sustained intraocular drug delivery in the eye of a subject in need thereof, wherein the IOL is associated with wherein said one or more drug-releasing articles comprise one or more active agents, said one or more drug-releasing articles within 7 days after implantation The article releases said one or more active agents resulting in an inflammation score of at most 1 as measured by an anterior chamber cell score using slit lamp biomicroscopy, or a 10 point visual A method that eliminates eye pain as measured by an analogue scale.
[Item 27] Within 7 days after implantation, the one or more drug-releasing articles release the one or more active agents, resulting in anterior chamber cell cytotoxicity using slit-lamp biomicroscopy. 27. The method of item 26, wherein the inflammation score is at most 1 as measured by the score.
[Item 28] Within 7 days after implantation, said one or more drug-releasing articles release said one or more active agents resulting in ocular pain as measured by a 10-point visual analogue scale. 28. The method of item 26 or 27, wherein
[Item 29] The method of any one of the preceding items, wherein the one or more drug-releasing articles are coupled to one or more haptics of the IOL.
[Item 30] The method of Item 29, wherein one of the one or more drug-releasing articles is associated with one of the one or more haptics of the IOL.
[Item 31] The method of item 29, wherein two of the one or more drug-releasing articles are coupled to one of the one or more haptics of the IOL.
[Item 32] The method of any one of the preceding items, wherein the one or more drug release articles comprise a biocompatible matrix.
[Item 33] Item 32, wherein the biocompatible matrix comprises a copolymer derived from about 20% to about 60% by weight caprolactone monomer and about 40% to 80% by weight of at least one other monomer. described method.
[Item 34] The method of any one of the preceding items, wherein said one or more drug release articles comprises about 1 μg to 800 μg of said one or more active agents.
[Item 35] The method of any one of the preceding items, wherein the one or more active agents is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate.
[Item 36] The method of any one of the preceding items, wherein the subject is undergoing or has undergone concurrent eye surgery.
[Item 37] The method of any one of the preceding items, wherein the subject is undergoing or has undergone concurrent cataract surgery.
[Item 38] A method of preparing at least one active agent-releasing intraocular lens, comprising:
(a) combining one or more active or diagnostic agents with a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer, thereby producing one or more ophthalmic articles; and
(b) coupling said one or more ophthalmic articles to one or more haptics of at least one intraocular lens (IOL).
[Item 39] The method of Item 38, wherein about one of the one or more ophthalmic articles couples with one of the one or more haptics of the IOL.
[Item 40] The method of Item 38 or 39, wherein about two of the one or more ophthalmic articles are coupled to one of the one or more haptics of the IOL.
[Item 41] The above items, wherein the biocompatible matrix comprises a copolymer derived from about 20% to about 60% by weight caprolactone monomer and about 40% to 80% by weight of at least one other monomer. A method according to any one of paragraphs.
42. The method of any one of the preceding items, wherein the one or more ophthalmic articles have an elongation to break of at least about 100% as measured by a tensile test.
[Item 43] The method of any one of the preceding items, wherein the one or more active agents is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate.
[Item 44] The method of any one of the preceding items, wherein the coupling comprises an indirect coupling between the one or more ophthalmic articles and the one or more haptics.
[Item 45] The method of any one of the preceding items, wherein the one or more ophthalmic articles include an internal structure for coupling around the one or more haptics.
[Item 46] The method of item 45, wherein the perimeter or maximum width of the internal structure is less than or equal to the perimeter or maximum width of the one or more haptics.
[Item 47] A method of administering an active agent or a diagnostic agent, comprising:
(a) compressing an intraocular lens (IOL) to which one or more ophthalmic articles are attached through an IOL injector comprising an injector tip inner diameter of about 0.5 mm to 3 mm, thereby compressing one or more ophthalmic producing a compressed IOL to which the articles are attached, wherein the one or more ophthalmic articles comprise one or more active or diagnostic agents;
(b) administering said compressed IOL having one or more ophthalmic articles attached thereto for sustained intraocular active or diagnostic agent delivery to the eye of a subject in need of administration of the active agent or diagnostic agent; and embedding in the method.
[Item 48] The method of item 47, wherein the one or more ophthalmic articles comprise a biocompatible matrix.
[Item 49] Item 48, wherein the biocompatible matrix comprises a copolymer derived from about 20% to about 60% by weight caprolactone monomer and about 40% to 80% by weight of at least one other monomer. described method.
[Item 50] The method of item 48 or 49, wherein the biocompatible matrix is sufficiently compressible to be compatible with injection by an IOL injector containing an injector tip inner diameter of about 0.5 mm to 3 mm.
[Item 51] The method of any one of items 48-50, wherein the one or more ophthalmic articles have a tensile strength of at least about 0.5 megapascals (MPa).
[Item 52] The method of any one of the preceding items, wherein the one or more ophthalmic articles have a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry.
[Item 53] The method of any one of the preceding items, wherein the one or more ophthalmic articles have a modulus of elasticity of at most about 3 MPa.
54. The method of any one of the preceding items, wherein the one or more ophthalmic articles have an elongation to break of at least about 100% as measured by a tensile test.
[Item 55] The compressing comprises tubularly collapsing the IOL with the one or more ophthalmic articles coupled thereto through the IOL injector comprising an injector tip inner diameter of about 0.5 mm to 3 mm. A method according to any one of the preceding items.
[Item 56] (1) a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer; and (2) one or more ophthalmic agents comprising one or more active agents or diagnostic agents. a container containing an article for
Kit including instructions for use.
[Item 57] The kit of item 56, further comprising another container comprising one or more intraocular lenses, each of said one or more intraocular lenses comprising one or more haptics.
[Item 58] The kit of item 56, wherein the container further comprises one or more intraocular lenses comprising one or more haptics associated with the one or more ophthalmic articles.
[Item 59] The kit of items 57 or 58, wherein one of said one or more ophthalmic articles is associated with said one or more haptics.
[Item 60] The kit of items 57 or 58, wherein two of said one or more ophthalmic articles are associated with said one or more haptics.
[Item 61] Any one of the preceding items, wherein the copolymer is derived from about 20% to about 60% by weight of the caprolactone monomer and about 40% to 80% by weight of the at least one other monomer. Kit described in .
[Item 62] The kit of any one of the preceding items, wherein the one or more active agents is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate.
[Item 63] The kit of any one of the preceding items, further comprising one or more intraocular device injectors.
[Item 64] A method of diagnosing an ocular disease or condition comprising providing an intraocular lens (IOL) to the eye of a subject in need thereof for delivering one or more diagnostic agents to the eye of the subject. administering, wherein the IOL comprises one or more ophthalmic articles attached thereto, said one or more ophthalmic articles comprising a paramagnetic molecule, a fluorescent compound, a magnetic molecule, a radionuclide, x A method comprising said one or more diagnostic agents selected from the group consisting of line imaging agents and contrast agents.
65. The method of claim 64, further comprising capturing an image containing said one or more diagnostic agents indicative of said disease or condition.
[Item 66] Prior to administering said IOL having one or more ophthalmic articles attached thereto, coupling said one or more ophthalmic articles to one or more haptics of said IOL. 66. The method of item 64 or 65, comprising:
[Item 67] Prior to administering said IOL to which said one or more ophthalmic articles are attached, one or more diagnostic agents are combined with a biocompatible matrix, thereby A method according to any one of the preceding items, comprising producing an ophthalmic article.
[Item 68] Prior to administering the IOL to which the one or more ophthalmic articles are attached, reduce the IOL to which the one or more ophthalmic articles are attached by about 0.5 to A method according to any one of the preceding items comprising compressing through an IOL injector comprising an injector tip inner diameter of 3 mm.
[Item 69] The method of any one of the preceding items, wherein the one or more diagnostic agents is a fluorescent compound.
[Item 70] The method of any one of the preceding items, wherein the one or more ophthalmic articles comprises a biocompatible copolymer matrix.
[Item 71] In Item 70, wherein the biocompatible matrix comprises a copolymer derived from about 20% to about 60% by weight caprolactone monomer and about 40% to 80% by weight of at least one other monomer. described method.
Claims (25)
ｂ．活性剤または診断剤
を含む眼科用物品であって、眼内レンズ（ＩＯＬ）のハプティクスの外表面に接触し、眼内レンズ（ＩＯＬ）のハプティクスの外表面の周囲に隣接して包含されるように構成されている眼科用物品。 a. a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer; and b. An ophthalmic article comprising an active agent or diagnostic agent for contacting and contained adjacent to the outer surface of the intraocular lens (IOL) haptics. An ophthalmic article comprising:
（ｉ）示差走査熱量測定法によって測定して最大でも約２４℃のガラス転移温度を有する、および／または
（ｉｉ）動的機械分析によって測定して最大でも約１０ＭＰａの弾性率を有する、
請求項１～４のいずれか一項に記載の眼科用物品。 Said goods are:
(i) has a glass transition temperature of at most about 24° C. as measured by differential scanning calorimetry; and/or (ii) has an elastic modulus of at most about 10 MPa as measured by dynamic mechanical analysis.
An ophthalmic article according to any one of claims 1-4.
ａ．（１）カプロラクトンモノマーおよび少なくとも１種の他のモノマーに由来するコポリマーを含む生体適合性マトリックス；および（２）活性剤または診断剤を含む１つまたは複数の眼科用物品；および
ｂ．１つまたは複数のハプティクスを含む１つまたは複数の眼内レンズ
を含み、眼科用物品が、眼内レンズのハプティクスの外表面に接触し、眼内レンズ（のハプティクスの外表面の周囲に隣接して包含されるように構成されている、前記キット。 A kit for ophthalmic delivery comprising:
a. (1) a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer; and (2) one or more ophthalmic articles comprising an active agent or diagnostic agent; and b. Including one or more intraocular lenses including one or more haptics, wherein the ophthalmic article contacts the outer surface of the haptics of the intraocular lens and is adjacent to the periphery of the outer surface of the haptics of the intraocular lens. The kit, wherein the kit is configured to be contained in a
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962867233P | 2019-06-27 | 2019-06-27 | |
| US62/867,233 | 2019-06-27 | ||
| US202063012994P | 2020-04-21 | 2020-04-21 | |
| US63/012,994 | 2020-04-21 | ||
| PCT/US2020/039990 WO2020264425A1 (en) | 2019-06-27 | 2020-06-26 | Ocular device delivery methods and systems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022538347A JP2022538347A (en) | 2022-09-01 |
| JPWO2020264425A5 true JPWO2020264425A5 (en) | 2023-07-04 |
Family
ID=74044213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021577919A Pending JP2022538347A (en) | 2019-06-27 | 2020-06-26 | Ophthalmic device delivery method and system |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11185441B2 (en) |
| EP (1) | EP3990042A4 (en) |
| JP (1) | JP2022538347A (en) |
| KR (1) | KR20220036946A (en) |
| CN (2) | CN117531051A (en) |
| AU (1) | AU2020302924A1 (en) |
| BR (1) | BR112021026265A2 (en) |
| CA (1) | CA3144406A1 (en) |
| GB (1) | GB2601922B (en) |
| IL (1) | IL289374A (en) |
| MX (1) | MX2021015760A (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020023290A1 (en) * | 2018-07-23 | 2020-01-30 | The Regents Of The University Of Colorado, A Body Corporate | Ophthalmic device for drug delivery |
| US11399977B2 (en) * | 2020-06-04 | 2022-08-02 | SpyGlass Pharma, Inc. | Ophthalmic implant system for drug delivery |
| US20220104936A1 (en) | 2020-10-05 | 2022-04-07 | SpyGlass Pharma, Inc. | IOL with Drug Delivery Devices and Uninterrupted PCO Barrier Edge |
| WO2023009654A2 (en) * | 2021-07-28 | 2023-02-02 | SpyGlass Pharma, Inc. | Stabilized intraocular drug delivery systems and methods of use |
| AU2022319758A1 (en) | 2021-07-30 | 2024-01-25 | SpyGlass Pharma, Inc. | Systems to affix devices to intraocular lens assemblies and related methods |
| CN114381083B (en) * | 2021-12-17 | 2023-03-24 | 浙江理工大学上虞工业技术研究院有限公司 | Antibacterial and antioxidant hydrogel for corneal contact lens and preparation method thereof |
| DE102022112803B4 (en) | 2022-05-20 | 2023-12-14 | Carl Zeiss Meditec Ag | Intraocular lens with a medication reservoir, arranged on a haptic arm in a radial recess |
| US20240024092A1 (en) * | 2022-07-22 | 2024-01-25 | SpyGlass Pharma, Inc. | Intraocular drug delivery systems and methods of use |
| WO2024091668A1 (en) * | 2022-10-27 | 2024-05-02 | JelliSee Ophthalmics Inc. | Drug delivering stretch ring |
| US20240148488A1 (en) * | 2022-11-04 | 2024-05-09 | JelliSee Ophthalmics Inc. | Dissolvable stretch ring for intraocular lens |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681102A (en) | 1985-09-11 | 1987-07-21 | Bartell Michael T | Apparatus and method for insertion of an intra-ocular lens |
| US4834750A (en) | 1987-09-17 | 1989-05-30 | Ioptex Research, Inc. | Deformable-elastic intraocular lens |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5290892A (en) | 1990-11-07 | 1994-03-01 | Nestle S.A. | Flexible intraocular lenses made from high refractive index polymers |
| US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5554187A (en) | 1995-08-18 | 1996-09-10 | Rizzo, Iii; Joseph | Medication dispensing intra-ocular lens system |
| US20020164374A1 (en) | 1997-10-29 | 2002-11-07 | John Jackson | Polymeric systems for drug delivery and uses thereof |
| US6679605B2 (en) | 2000-05-22 | 2004-01-20 | Medennium, Inc. | Crystalline polymeric compositions for ophthalmic devices |
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| EP3167872B1 (en) | 2000-07-05 | 2020-10-14 | Allergan, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| AU2002236495B2 (en) | 2000-11-29 | 2006-05-11 | Allergan, Inc. | Intraocular implants for preventing transplant rejection in the eye |
| US6713081B2 (en) | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| WO2003061625A2 (en) | 2002-01-18 | 2003-07-31 | Snyder Michael E | Sustained release ophthalmological device and method of making and using the same |
| US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| EP2918296A1 (en) | 2003-02-28 | 2015-09-16 | Biointeractions Ltd. | Polymeric network system for medical devices and methods of use |
| CN101137338A (en) * | 2003-12-03 | 2008-03-05 | 眼睛光学技术公司 | Hybrid accommodating intraocular lens |
| US8455656B2 (en) | 2004-04-30 | 2013-06-04 | Allergan, Inc. | Kinase inhibitors |
| US20050244458A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8512738B2 (en) | 2004-04-30 | 2013-08-20 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase implants |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| EP1611877A1 (en) | 2004-06-28 | 2006-01-04 | Universidade de Coimbra | Method for preparing sustained-release therapeutic ophthalmic articles using compressed fluids for impregnation of drugs |
| EP1773350B1 (en) | 2004-07-12 | 2013-05-29 | Allergan, Inc. | Opthalmic compositions for treating ophthalmic conditions |
| US7931909B2 (en) | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| WO2007084582A2 (en) | 2006-01-17 | 2007-07-26 | Forsight Labs, Llc | Drug delivery treatment device |
| US20070178138A1 (en) | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
| WO2007112946A1 (en) * | 2006-03-30 | 2007-10-11 | Universite De Geneve | Intraocular lens with drug delivery system attached thereto |
| US8216603B2 (en) | 2006-05-04 | 2012-07-10 | Herbert Edward Kaufman | Method, device, and system for delivery of therapeutic agents to the eye |
| US20070260203A1 (en) | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8846073B2 (en) | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
| CA2680831A1 (en) | 2007-03-14 | 2008-09-18 | University Of Washington | Device and method for intraocular drug delivery |
| US8231892B2 (en) | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
| US8138290B2 (en) | 2008-01-25 | 2012-03-20 | Bausch & Lomb Incorporated | High water content ophthalmic devices |
| US8702794B2 (en) | 2008-04-28 | 2014-04-22 | Abbott Medical Optics Inc. | Back loaded IOL insertion cartridge |
| US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| WO2009140246A2 (en) | 2008-05-12 | 2009-11-19 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US10588855B2 (en) | 2008-05-12 | 2020-03-17 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US8821870B2 (en) | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| US8343214B2 (en) | 2008-10-20 | 2013-01-01 | Cateract Innovations LLC | Apparatus for the treatment of cataract |
| MX2011005272A (en) | 2008-11-20 | 2011-06-21 | Insight Innovations Llc | Biocompatible biodegradable intraocular implant system. |
| US20120232649A1 (en) * | 2008-11-20 | 2012-09-13 | Insight Innovations, Llc | Intraocular Lens Cell Migration Inhibition System |
| JP2012511395A (en) * | 2008-12-11 | 2012-05-24 | マサチューセッツ インスティテュート オブ テクノロジー | Contact lens drug delivery device |
| CA2979355C (en) * | 2009-05-18 | 2023-02-21 | Dose Medical Corporation | Drug eluting ocular implant |
| JP5695035B2 (en) | 2009-06-03 | 2015-04-01 | フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． | Anterior eye drug supply |
| JP5886204B2 (en) | 2009-10-30 | 2016-03-16 | アトーン ファルマ、インコーポレイテッドＡｔｏｎ Ｐｈａｒｍａ，Ｉｎｃ． | Intraocular drug delivery device |
| US20130273137A1 (en) | 2010-05-03 | 2013-10-17 | Massachusetts Eye & Ear Infirmary | Drug delivery coating and devices |
| JP2013526572A (en) | 2010-05-17 | 2013-06-24 | アエリエ・ファーマシューティカルズ・インコーポレーテッド | Drug delivery device for the delivery of eye treatments |
| EP2591025B1 (en) | 2010-07-05 | 2016-10-05 | Dave, Jagrat Natavar | Polymeric composition for ocular devices |
| SG187786A1 (en) | 2010-08-12 | 2013-03-28 | Univ Nanyang Tech | A biodegradable ocular implant |
| WO2012149287A1 (en) | 2011-04-29 | 2012-11-01 | Allergan, Inc. | Solvent cast film sustained release latanoprost implant |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| AU2012308317B2 (en) | 2011-09-14 | 2017-01-05 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
| US20130302420A1 (en) | 2012-05-14 | 2013-11-14 | Barry L. Bowyer | Ocular biodegradable drug implant and method of its use |
| SG11201500710QA (en) * | 2012-08-15 | 2015-02-27 | Univ Nanyang Tech | A drug eluting member, a method of attaching the same and a method of fabricating the same, a device for holding the same and a drug eluting device |
| JP6317748B2 (en) | 2012-09-27 | 2018-04-25 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | Biodegradable drug delivery system for sustained protein release |
| WO2014066644A1 (en) | 2012-10-26 | 2014-05-01 | Allergan, Inc. | Ketorolac-containing sustained release drug delivery systems |
| HUE046128T2 (en) | 2012-10-26 | 2020-02-28 | Forsight Vision5 Inc | Ophthalmic system for sustained release of drug to eye |
| WO2014066658A1 (en) | 2012-10-26 | 2014-05-01 | Allergan, Inc. | Ketorolac-containing sustained release drug delivery systems |
| JP6511401B2 (en) | 2013-02-15 | 2019-05-15 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | Sustained drug delivery implant |
| JP6675298B2 (en) | 2013-03-15 | 2020-04-01 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | Prostamide-containing intraocular implant |
| WO2014179568A2 (en) | 2013-05-02 | 2014-11-06 | Odin Biotech | Two-layer ocular implant |
| CN110302138B (en) | 2013-10-31 | 2022-09-30 | 阿勒根公司 | Prostamide-containing intraocular implants and methods of use thereof |
| EP3068372B1 (en) | 2013-11-14 | 2019-05-08 | EyeD Pharma | Eye device |
| CA2932015A1 (en) | 2013-12-06 | 2015-06-11 | Envisia Therapeutics Inc. | Intracameral implant for treatment of an ocular condition |
| EP3067015B1 (en) | 2015-03-10 | 2018-06-06 | Consejo Superior De Investigaciones Científicas | Photochemically induced engagement of intraocular implants |
| US20180177718A1 (en) | 2015-05-29 | 2018-06-28 | Envisia Therapeutics, Inc. | Implant for treatment of an ocular condition |
| US20210228408A1 (en) | 2015-07-23 | 2021-07-29 | Allergan, Inc. | Glaucoma Treatment Via Intracameral Ocular Implants |
| WO2017053686A1 (en) | 2015-09-24 | 2017-03-30 | Massachusetts Eye And Ear Infirmary | Drug delivery system and methods of use |
| GB201519811D0 (en) | 2015-11-10 | 2015-12-23 | Univ Belfast | Ocular compositions |
| CN106729975B (en) | 2015-11-19 | 2020-04-14 | 爱博诺德(北京)医疗科技股份有限公司 | Material for producing artificial lens |
| CN106901871B (en) * | 2015-12-23 | 2021-08-24 | 爱博诺德(北京)医疗科技股份有限公司 | Intraocular lens with one or more additional portions |
| PT109154B (en) | 2016-02-12 | 2019-11-05 | Univ De Coimbra | NON-INVASIVE EYE INSERT TECHNOLOGY FOR CONTROLLED DRUG RELEASE |
| EP3210572A1 (en) * | 2016-02-29 | 2017-08-30 | Elodie Jane Siney | Intraocular lens comprising drug-containing microspheres |
| AU2017252294B2 (en) | 2016-04-20 | 2021-12-02 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
| CA3038115A1 (en) | 2016-09-30 | 2018-04-05 | Mati Therapeutics Inc. | Ophthalmic drug sustained release formulation and uses thereof |
| US10603274B2 (en) | 2016-09-30 | 2020-03-31 | Mati Therapeutics Inc. | Ophthalmic drug sustained release formulation and uses thereof |
| CN110337296A (en) | 2016-12-27 | 2019-10-15 | 犹他大学研究基金会 | Intraocular drug delivery device and correlation technique |
| WO2018175268A1 (en) | 2017-03-19 | 2018-09-27 | Biohealthways, Inc. | Biodegrading implantable ocular sustained release drug delivery system |
| US11696952B2 (en) | 2017-08-17 | 2023-07-11 | Lutronic Vision Inc. | Nanocapsule-based ocular therapy |
| CN107595765A (en) | 2017-09-22 | 2018-01-19 | 沈阳兴齐眼药股份有限公司 | A kind of ophthalmically acceptable sustained release drug delivery system and preparation method thereof |
| US20190192341A1 (en) | 2017-11-09 | 2019-06-27 | Allergan, Inc. | Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect |
| JP6990321B2 (en) | 2018-02-22 | 2022-01-12 | イバンティス インコーポレイテッド | Ocular implants and delivery system |
| WO2020047144A2 (en) | 2018-08-30 | 2020-03-05 | Liu Yunxiang | Ophthalmic formulations, process for preparing the same and method for administering the same |
| DE102018129478B4 (en) | 2018-11-22 | 2021-05-27 | Carl Zeiss Meditec Ag | Ophthalmic implant with an active substance delivery system and method for producing such an ophthalmic implant |
| CN113365604A (en) | 2018-12-21 | 2021-09-07 | 瑞瓦纳治疗有限公司 | Ophthalmic composition |
| CN113301886A (en) | 2018-12-21 | 2021-08-24 | 瑞瓦纳治疗有限公司 | Coated ocular implant |
| US20200281767A1 (en) | 2019-03-10 | 2020-09-10 | Paloza Llc | Ocular agent delivery device, ocular monitoring device and methods thereof |
| US11039954B2 (en) | 2019-03-21 | 2021-06-22 | Microoptx Inc. | Implantable ocular drug delivery devices and methods |
-
2020
- 2020-06-26 EP EP20832323.8A patent/EP3990042A4/en active Pending
- 2020-06-26 GB GB2200660.5A patent/GB2601922B/en active Active
- 2020-06-26 CN CN202311350979.0A patent/CN117531051A/en active Pending
- 2020-06-26 MX MX2021015760A patent/MX2021015760A/en unknown
- 2020-06-26 JP JP2021577919A patent/JP2022538347A/en active Pending
- 2020-06-26 CA CA3144406A patent/CA3144406A1/en active Pending
- 2020-06-26 CN CN202080061083.9A patent/CN114340690B/en active Active
- 2020-06-26 BR BR112021026265A patent/BR112021026265A2/en unknown
- 2020-06-26 AU AU2020302924A patent/AU2020302924A1/en active Pending
- 2020-06-26 KR KR1020227003100A patent/KR20220036946A/en unknown
- 2020-07-21 US US16/935,027 patent/US11185441B2/en active Active
-
2021
- 2021-12-26 IL IL289374A patent/IL289374A/en unknown
-
2022
- 2022-05-12 US US17/742,847 patent/US20230042169A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2601922A (en) | Ocular device delivery methods and systems | |
| Lee et al. | Biodegradable implants for sustained drug release in the eye | |
| Ursell et al. | Anterior capsule stability in eyes with intraocular lenses made of poly (methyl methacrylate), silicone, and AcrySof | |
| Nishi et al. | Inhibition of migrating lens epithelial cells by blocking the adhesion molecule integrin: a preliminary report | |
| JP2018171519A (en) | Sustained drug delivery implant | |
| US11517422B2 (en) | Intraocular implants comprising drug-eluting materials with time release characteristics | |
| Avitabile et al. | Biocompatibility and biodegradation of intravitreal hyaluronan implants in rabbits | |
| CN104661647A (en) | Pharmaceutical nanoparticles showing improved mucosal transport | |
| JP7193448B2 (en) | Depot system containing glatiramer acetate | |
| KR20150058510A (en) | Biodegradable drug delivery systems for the sustained release of proteins | |
| JPWO2020264425A5 (en) | ||
| JPH04364855A (en) | Coated lens in eye and coating composition therefor | |
| Dong et al. | Intravitreal implantation of the biodegradable cyclosporin A drug delivery system for experimental chronic uveitis | |
| JP2020514404A (en) | Intraocular drug delivery device and related methods | |
| WO2020264425A1 (en) | Ocular device delivery methods and systems | |
| US20170105932A1 (en) | Intraocular drug delivery device and associated methods | |
| US20220218685A1 (en) | Composition for treating eye diseases | |
| JP2023547607A (en) | Intraocular implants containing active agents | |
| JPH08175984A (en) | Preventive of delayed cataract | |
| JP6543431B2 (en) | Intraocular drug delivery device and associated method | |
| El-Saadany et al. | Evaluation of aphakic iris-claw intraocular lens implantation | |
| Kiss et al. | Ocular implants–a novel approach in ocular drug delivery | |
| de Juan-Marcos et al. | Intravitreal dexamethasone implant migration to the anterior chamber in an aphakic child | |
| AU2013245543A1 (en) | Intraocular drug delivery device and associated methods |